Papers - Imai, Shungo

マスメディアの「医薬品」に関する報道が患者に及ぼす影響―インターネットパネルと保険薬局の来局者を対象としたアンケート調査―

今井俊吾，小野貴登，阿部真也，松井洸，卯田健太，佐山杏子，木﨑速人，山口　浩，野村和彦，堀　里子

医療薬学 50 ( 7 ) 319 - 327 2024

Research paper (scientific journal), Joint Work, Lead author, Corresponding author, Accepted

Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using a claims database: a retrospective cohort study

Takezo Tsutsumi, Shungo Imai, Kenji Momo, Hitoshi Kashiwagi, Yuki Sato, Mitsuru Sugawara, Yoh Takekuma

International Journal of Clinical Pharmacy 46 ( 2 ) 421 - 428 2023.12

Research paper (scientific journal), Joint Work, Accepted

Effects of body composition on renal function estimates in older patients

Soyoko Kaburaki, Shungo Imai, Hitoshi Kashiwagi, Yuki Sato, Mitsuru Sugawara, Yoh Takekuma

Biological and Pharmaceutical Bulletin 46 ( 11 ) 1609 - 1618 2023.11

Research paper (scientific journal), Joint Work, Accepted

Influence of voiced and semi-voiced sounds on the subjective similarity of different drug names: A cognitive psychological experiment

Kodai Yoshikawa, Hayato Kizaki, Shungo Imai, Satoko Hori

Biological and Pharmaceutical Bulletin 46 ( 11 ) 1630 - 1634 2023.11

Research paper (scientific journal), Accepted

Comparison of different sustained-release opioids and acute respiratory conditions in patients with cancer and chronic kidney disease

Satoru Mitsuboshi, Shungo Imai, Hayato Kizaki, Satoko Hori

Pharmacotherapy 44 ( 2 ) 122 - 130 2023.11

Research paper (scientific journal), Joint Work, Corresponding author, Accepted

A survey of the status of methadone switching in Japan using a hospital-based administrative claims database

Shungo Imai, Natsumi Aoki, Keisuke Ikegami, Hayato Kizaki, Satoko Hori

The Journal of Clinical Pharmacology 64 ( 2 ) 189 - 195 2023.09

Research paper (scientific journal), Lead author, Accepted

• Access to Document (DOI)

Risk factor analysis of vancomycin-induced nephrotoxicity in paediatric patients aged 0 - 1 year using Japanese medical database

Takayuki Miyai, Yoh Takekuma, Hitoshi Kashiwagi, Yuki Sato, Shunsuke Nashimoto, Mitsuru Sugawara, Shungo Imai

Biological & pharmaceutical bulletin 46 ( 6 ) 817 - 823 2023.06

Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted

• Access to Document (DOI)

A Novel Approach to Analyze the Factors Affecting Adverse Drug Reactions by Combination of Electronic Medical Record Database and Machine Learning Method

Shungo Imai

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 143 ( 6 ) 485 - 489 2023.06

Research paper (conference, symposium, etc.), Single Work, Lead author, Last author, Corresponding author

• Access to Document (DOI)

Detection of vaccine adverse events before package insert revisions using a Japanese spontaneous reporting system

Shimon Suzuki, Shungo Imai, Satoru Mitsuboshi, Hayato Kizaki, Masayuki Hashiguchi, Satoko Hori

The Journal of Clinical Pharmacology 63 ( 8 ) 903 - 908 2023.05

Research paper (scientific journal), Joint Work, Corresponding author, Accepted

Exploring factors affecting the occurrence of hypersensitivity reactions induced by nonionic iodine contrast media

Ryouichi Chatani, Sakura Kondo, Tadamasa Kamimura, Shinya Suzuki, Eriko Komatsubara, Seiichi Hayashi, Masayuki Hashiguchi, Hayato Kizaki, Shungo Imai, Satoko Hori

The Journal of Clinical Pharmacology 63 ( 9 ) 1002 - 1008 2023.04

Research paper (scientific journal), Joint Work, Accepted

• Access to Document (DOI)

Onset timing and duration of augmented renal clearance in a mixed intensive care unit

Ryusei Mikami, Mineji Hayakawa, Shungo Imai, Mitsuru Sugawara, Yoh Takekuma

Journal of Intensive Care 11 ( 1 ) 13 - 13 2023.03

Research paper (scientific journal), Joint Work, Accepted

• Access to Document (DOI)

Dysautonomia associated with immune checkpoint inhibitors

Toshiki Tezuka, Shinichi Okuzumi, Chiho Nakajima, Toshihiro Ide, Shungo Imai, Satoru Mitsuboshi, Yuki Kuwahara, Tsubasa Takizawa, Morinobu Seki, Naoto Minematsu, Naoko Aragane, Jin Nakahara, Satoko Hori, Shunya Nakane, Shigeaki Suzuki

Journal of Neurology 270 ( 7 ) 3413 - 3423 2023.03

Research paper (scientific journal), Joint Work, Accepted

• Access to Document (DOI)

Usefulness of the Albumin–Bilirubin Score in Determining the Initial Dose of Voriconazole for Patients with Liver Cirrhosis

Shunsuke Nashimoto, Shungo Imai, Mitsuru Sugawara, Yoh Takekuma

Biological and Pharmaceutical Bulletin 46 ( 2 ) 230 - 236 2023.02

Research paper (scientific journal), Joint Work, Accepted

• Access to Document (DOI)

Increased risk of Lambert-Eaton myasthenic syndrome (LEMS) in small cell lung cancer patients treated with immune checkpoint inhibitor

Shungo Imai, Satoru Mitsuboshi, Satoko Hori, Shigeaki Suzuki

European Journal of Cancer 180   1 - 3 2023.02

Research paper (scientific journal), Joint Work, Lead author, Accepted

Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia

Yuki Inoue, Yoh Takekuma, Takayuki Miyai, Hitoshi Kashiwagi, Yuki Sato, Mitsuru Sugawara, Shungo Imai

European journal of clinical pharmacology 79 ( 3 ) 415 - 425 2023.01

Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted

Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness

Ryusei Mikami, Mineji Hayakawa, Shungo Imai, Kunihiko Maekawa, Kojiro Yamazaki, Mitsuru Sugawara, Yoh Takekuma

Journal of Clinical Medicine 12 ( 3 ) 860 2023.01

Research paper (scientific journal), Accepted

病院における造影剤副作用マネジメントと薬剤部門の関わり方に関する実態調査

近藤咲良，鈴木信也，上村忠聖，木﨑速人，今井俊吾，堀　里子

医薬品情報学 25 ( 1 ) 31 - 37 2023.01

Research paper (scientific journal), Joint Work, Accepted

• Access to Document (DOI)

薬局におけるリフィル処方箋への対応に関する実態と薬剤師の意識 – 横断的質問紙調査 –

平田彩乃，木﨑速人，矢野良太郎，山村真一，吉岡ゆうこ，鈴木順子，今井俊吾，堀　里子

医薬品情報学 25 ( 1 ) 1 - 11 2023.01

Research paper (scientific journal), Joint Work, Accepted

• Access to Document (DOI)

Investigation of Prescription Status and Exploration of Risk Factors Related to Denosumab-Induced Hypocalcemia in Combination Therapy with 1α,25-Dihydroxy-vitamin D3.

Keisuke Ikegami, Megumi Saito, Shungo Imai, Hayato Kizaki, Osamu Yasumuro, Ryohkan Funakoshi, Satoko Hori

Biological and Pharmaceutical Bulletin 46 ( 1 ) 95 - 101 2023.01

Research paper (scientific journal), Joint Work, Accepted

• Access to Document (DOI)

Hepatic drug metabolism in older people with body composition changes.

Soyoko Kaburaki, Eri Yoshimura, Yasushi Miyamoto, Shungo Imai, Hitoshi Kashiwagi, Hidefumi Ueno, Mitsuru Sugawara, Yoh Takekuma

Geriatrics & gerontology international (Wiley)  22 ( 5 ) 449 - 454 2022.03

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1444-1586

　View Summary

AIM: Dosage adjustment is essential in older individuals because they are prone to experience a decline in liver function and changes in body composition. However, quantitative tests or equations for evaluating the activity of hepatic drug metabolism have not yet been clearly established. We examined hepatic drug metabolism activities in older individuals, focusing on changes in body composition parameters. METHODS: Lansoprazole and nifedipine, substrates of the metabolic enzymes cytochrome P450 (CYP) 2C19 and 3A4, respectively, were selected to study hepatic drug metabolism. Residual samples from blood test for older patients were evaluated to determine drug metabolism. The body composition of relevant patients was determined by analyzing characteristic parameters of skeletal muscle mass index (SMI), handgrip strength (HGS) and hepatic steatosis index (HSI). The differences in hepatic drug metabolism were studied statistically among categories in terms of the cut-off value of these parameters. RESULTS: Older male patients receiving lansoprazole and nifedipine in the low SMI (<7.0 kg/m2 ) category showed an 85-90% reduction in respective CYP2C19 and CYP3A4 metabolic activities compared with the normal SMI category. For the female patients, CYP2C19 and CYP3A4 metabolic activities showed no significant correlation with SMI and HGS. Fatty liver disease (HSI ≥36) was found to reduce CYP2C19 metabolic activity particularly in older female patients. CONCLUSIONS: Low CYP2C19 metabolic activity was statistically correlated with low SMI in male patients and high HSI in female patients, whereas low CYP3A4 metabolic activity was statistically correlated with low HGS in male patients.

• Access to Document (DOI)